ATAI Life Sciences BV Asset Resilience Ratio
ATAI Life Sciences BV asset resilience ratio. ATAI Life Sciences BV (ATAI) has an Asset Resilience Ratio of 70.85% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ATAI defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of ATAI Life Sciences BV (2021–2025)
Asset resilience ratio of ATAI Life Sciences BV from 2021 to 2025. This chart shows how ATAI Life Sciences BV's Asset Resilience Ratio has changed over time. Read ATAI total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down ATAI Life Sciences BV's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ATAI total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $187.66 Million | 70.85% |
| Total Liquid Assets | $187.66 Million | 70.85% |
Asset Resilience Insights
- Very High Liquidity: ATAI Life Sciences BV maintains exceptional liquid asset reserves at 70.85% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ATAI Life Sciences BV Industry Peers by Asset Resilience Ratio
Compare ATAI Life Sciences BV's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Chengdu Easton Biopharmaceuticals Co Ltd
SHG:688513 |
Biotechnology | 35.16% |
|
China Resources Boya Bio pharmaceutical Group Co Ltd
SHE:300294 |
Biotechnology | 23.15% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Achieve Life Sciences Inc
F:SP4P |
Biotechnology | 3.60% |
ATAI Life Sciences BV Asset Resilience Ratio by Year (2021–2025)
ATAI Life Sciences BV asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for ATAI Life Sciences BV.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 54.98% | $170.74 Million | $310.54 Million | +26.86pp |
| 2024-12-31 | 28.12% | $44.83 Million | $159.39 Million | -17.61pp |
| 2023-12-31 | 45.74% | $134.22 Million | $293.48 Million | +18.73pp |
| 2022-12-31 | 27.01% | $82.50 Million | $305.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $414.17 Million | -- |
About ATAI Life Sciences BV
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more